CUMYL-CB-MEGACLONE

CUMYL-CB-MEGACLONE (CUMYL-CBMGACLONE, SGT-273) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in April 2020.[1]

CUMYL-CB-MEGACLONE
Legal status
Legal status
Identifiers
  • 2,5-Dihydro-2-(1-methyl-1-phenylethyl)-5-(cyclobutylmethyl)-1H-pyrido[4,3-b]indol-1-one
Chemical and physical data
FormulaC25H26N2O
Molar mass370.496 g·mol−1
3D model (JSmol)
  • CC(C)(c1ccccc1)N5C=Cc4n(CC2CCC2)c3ccccc3c4C5=O
  • InChI=1S/C25H26N2O/c1-25(2,19-11-4-3-5-12-19)27-16-15-22-23(24(27)28)20-13-6-7-14-21(20)26(22)17-18-9-8-10-18/h3-7,11-16,18H,8-10,17H2,1-2H
  • Key:XABXFXHKUHKHFO-UHFFFAOYSA-N

See also

References
  1. Analytical data for Cumyl-Cb-MeGaClone. Hungarian Institute for Forensic Science, 9 April 2020
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.